Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SELECTA BIOSCIENCES, INC.

(SELB)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 09/21 10:18:09 am
4.285 USD   +2.76%
08:01aSelecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
GL
09/20SELECTA BIOSCIENCES : Names Kevin Tan Finance Chief
MT
09/20SELECTA BIOSCIENCES : Hires Kevin Tan as CFO
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
4.27(c) 4.17(c) 4.45(c) 4.17(c) 4.2401 Last
1 070 270 427 969 3 826 356 1 581 973 105 691 Volume
+6.48% -2.34% +6.71% -6.29% +1.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 55,1 M - -
Net income 2021 -36,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -20,2x
Yield 2021 -
Sales 2022 40,7 M - -
Net income 2022 -55,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -9,18x
Yield 2022 -
Capitalization 480 M 480 M -
Capi. / Sales 2021 8,70x
Capi. / Sales 2022 11,8x
Nbr of Employees 44
Free-Float 71,6%
More Financials
Company
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its... 
More about the company
Ratings of Selecta Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SELECTA BIOSCIENCES, INC.
08:01aSelecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
GL
09/20SELECTA BIOSCIENCES : Names Kevin Tan Finance Chief
MT
09/20SELECTA BIOSCIENCES : Hires Kevin Tan as CFO
MT
09/20SELECTA BIOSCIENCES INC : Change in Directors or Principal Officers (form 8-K)
AQ
09/20SELECTA BIOSCIENCES : Announces Appointment of Kevin Tan as Chief Financial Officer
AQ
09/09SELECTA BIOSCIENCES : to Participate at the H.C. Wainwright 23rd Annual Global Investment ..
AQ
09/08SELECTA BIOSCIENCES : Cyrus Biotechnology Collaborating to Create Engineered Therapeutic P..
MT
09/08SELECTA BIOSCIENCES INC : Other Events (form 8-K)
AQ
09/08Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Enginee..
GL
09/08Selecta Biosciences and Cyrus Biotechnology Enters Collaboration to Create Novel Engine..
CI
08/12SELECTA BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/12SELECTA BIOSCIENCES : Reports Second Quarter 2021 Financial Results and Provides Business ..
PU
08/12SELECTA BIOSCIENCES INC : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/12Selecta Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
08/12Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business..
GL
More news
News in other languages on SELECTA BIOSCIENCES, INC.
09/20Selecta Biosciences nomme Kevin Tan au poste de directeur financier
09/20Selecta Biosciences recrute Kevin Tan comme directeur financier
09/08Selecta Biosciences et Cyrus Biotechnology collaborent pour créer des protéines thérape..
05/03ESPÍAS, SATÉLITES Y ABOGADOS : compradores de soja aprietan a los agricultores brasileños
More news
Analyst Recommendations on SELECTA BIOSCIENCES, INC.
More recommendations
Chart SELECTA BIOSCIENCES, INC.
Duration : Period :
Selecta Biosciences, Inc. Technical Analysis Chart | SELB | US8162121045 | MarketScreener
Technical analysis trends SELECTA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,17 $
Average target price 8,67 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Carsten Brunn President, Chief Executive Officer & Director
Ann K. Donohue VP, Chief Financial & Accounting Officer
Carrie Smith Cox Chairman
Lloyd Johnston COO, Senior Vice President-Research & Development
Takashi Kei Kishimoto Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
SELECTA BIOSCIENCES, INC.37.62%480
GILEAD SCIENCES, INC.21.80%88 970
BIONTECH SE315.86%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS32.66%66 632
VERTEX PHARMACEUTICALS-21.44%48 168